Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily 20 Year Treasury Bull 3X Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.7 (market cap $2.06B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 62.2× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TMF | VRTX | |
|---|---|---|
Market Cap | $2.06B | $128.16B |
Volume | 10,528,006 | 806,603 |
Sector | Fixed Income | Health |
52-Week High | $44.14 | $557.96 |
52-Week Low | $25.19 | $407.37 |
Typical Hold Time | 28 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.23, down 0.51% with elevated trading volume of 5.2 million shares. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oversold RSI readings suggest potential for near-term bounce. The ETF saw increased investor interest amid bond market volatility.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risk. Current oversold conditions may present tactical opportunities, though the bearish technical structure and interest rate sensitivity require careful risk management for investors seeking directional bond exposure.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
